Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Diabetes Therapy Springer Nature Link Amylin Derivative an overview ScienceDirect Topics Glucagon like peptide 1 receptor: mechanisms and advances in therapy Signal Transduction and Targeted Therapy Development of the novel amylin receptor activators with nanomolar potency by peptide mutagenesis bioRxiv